Application of the Left Ventricular Pressure–Strain Loop Technique in Monitoring Improvement Factors of Patients With Heart Failure Reduced Ejection Fraction

IF 3.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Qing Li, Yaolei Guo, Xiaomin Tang, Chang Liu, Zhidong Wang, Qianping Gao, Yuanshi Li, Junxian Cao
{"title":"Application of the Left Ventricular Pressure–Strain Loop Technique in Monitoring Improvement Factors of Patients With Heart Failure Reduced Ejection Fraction","authors":"Qing Li,&nbsp;Yaolei Guo,&nbsp;Xiaomin Tang,&nbsp;Chang Liu,&nbsp;Zhidong Wang,&nbsp;Qianping Gao,&nbsp;Yuanshi Li,&nbsp;Junxian Cao","doi":"10.1155/cdr/5562513","DOIUrl":null,"url":null,"abstract":"<p>The left ventricular pressure–strain loop (PSL) is a new technique based on ultrasound for noninvasive quantitative evaluation of global and local myocardial work (MW). This study is aimed at evaluating improvement factors of patients with heart failure (HF) reduced ejection fraction (HFrEF) using the PSL technique. A total of 88 patients with HF were enrolled in this study, which had ≤ 40% left ventricular ejection fraction (LVEF). The EchoPAC workstation was used to obtain the global longitudinal strain (GLS) and MW parameters of the left ventricle. All patients have taken medicines for HF treatments for 6–12 months. The improvements of HF after therapies were evaluated according to the following recommended criteria. The clinical characteristics of patients with improved and nonimproved groups were stratified via univariate or multivariate logistic regression analysis, receiver operating characteristic (ROC), and the area under ROC (area under the curve (AUC)). There were no significant differences in general medical information, the underlying diseases, laboratory findings, myocardial enzyme activities, and taking medicines between the improved and nonimproved LVEF patients (<i>p</i> &gt; 0.05). There were significant differences in LVEF of patients at admission, left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness (IVST), early diastolic mitral flow peak velocity E (E peak), GLS, global myocardial work index (GWI), global myocardial constructive work (GCW), and global myocardial work efficiency (GWE) between the two groups (<i>p</i> &lt; 0.05). Univariate and multivariate logistic regression analyses confirmed that GWI and GCW were critical predictive factors for LVEF improvement in patients with HF. ROC curve showed that the AUC of GWI and GCW were 0.796 and 0.779 at the cut-off of 741 mmHg% for GWI and 973.5 mmHg% for GCW, respectively. The sensitivities of GWI and GCW were 65% and 75%, and the specificities of GWI and GCW were 83.3% and 79.2% at given cut-off values. These results revealed that GWI and GCW were independent predictors of improvement of LVEF in patients with HFrEF.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2024 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/5562513","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/5562513","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

The left ventricular pressure–strain loop (PSL) is a new technique based on ultrasound for noninvasive quantitative evaluation of global and local myocardial work (MW). This study is aimed at evaluating improvement factors of patients with heart failure (HF) reduced ejection fraction (HFrEF) using the PSL technique. A total of 88 patients with HF were enrolled in this study, which had ≤ 40% left ventricular ejection fraction (LVEF). The EchoPAC workstation was used to obtain the global longitudinal strain (GLS) and MW parameters of the left ventricle. All patients have taken medicines for HF treatments for 6–12 months. The improvements of HF after therapies were evaluated according to the following recommended criteria. The clinical characteristics of patients with improved and nonimproved groups were stratified via univariate or multivariate logistic regression analysis, receiver operating characteristic (ROC), and the area under ROC (area under the curve (AUC)). There were no significant differences in general medical information, the underlying diseases, laboratory findings, myocardial enzyme activities, and taking medicines between the improved and nonimproved LVEF patients (p > 0.05). There were significant differences in LVEF of patients at admission, left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness (IVST), early diastolic mitral flow peak velocity E (E peak), GLS, global myocardial work index (GWI), global myocardial constructive work (GCW), and global myocardial work efficiency (GWE) between the two groups (p < 0.05). Univariate and multivariate logistic regression analyses confirmed that GWI and GCW were critical predictive factors for LVEF improvement in patients with HF. ROC curve showed that the AUC of GWI and GCW were 0.796 and 0.779 at the cut-off of 741 mmHg% for GWI and 973.5 mmHg% for GCW, respectively. The sensitivities of GWI and GCW were 65% and 75%, and the specificities of GWI and GCW were 83.3% and 79.2% at given cut-off values. These results revealed that GWI and GCW were independent predictors of improvement of LVEF in patients with HFrEF.

Abstract Image

求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Therapeutics
Cardiovascular Therapeutics 医学-心血管系统
CiteScore
5.60
自引率
0.00%
发文量
55
审稿时长
6 months
期刊介绍: Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信